The court said that it cannot decide the plea against the company on the basis of a judgment passed by a US court against Ranbaxy
The Supreme Court today dismissed a PIL (public interest petition) seeking a probe against Ranbaxy Laboratories for allegedly manufacturing and selling substandard 
medicines due to lack of evidence against the company.
A bench of justices AK Patnaik and Ranjan Gogoi, however, allowed the petitioner, advocate ML Sharma, to file a fresh petition if he finds some evidence against the company in support of his allegation that the company is engaged in manufacturing and selling substandard drugs.
The bench said that it cannot decide the plea against the company on the basis of a judgment passed by a US court against Ranbaxy.
“Your entire argument is based on proceedings in the US. We have no jurisdiction over it. Show us material that things are happening in India and it adversely affects right to life of people here,” the bench observed adding, “Where is the material against Ranbaxy.”
“No material has been placed to show that drugs manufactured by any unit of Ranbaxy are substandard, adulterated, spurious and that such drugs are prohibited under the law. In the absence of such material, we cannot entertain the plea,” the bench said.
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
